Comparison of 18F-FDG and 11C-choline PET/CT for detecting recurrences in patients with nonsquamous cell head and neck malignancies

Nuclear Medicine Communications

Volumn 31, Issue 11, 2010, Pages 931-937

  Ito, Kimiteru ^a   Yokoyama, Jyunkichi ^b   Kubota, Kazuo ^c   Morooka, Miyako ^c  

^a SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^b TOCHIGI CANCER CENTER   (Japan)

^c NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

adenocarcinoma; choline; fluorodeoxyglucose; nonsquamous cell head and neck malignancies; positron emission tomography computed tomography; sarcoma

Indexed keywords

CHOLINE C 11; CISPLATIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; CARBON; CHOLINE; DIAGNOSTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BRAIN DAMAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SCINTISCANNING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SURVEILLANCE; FEMALE; HEAD AND NECK CANCER; HUMAN; IMAGE ANALYSIS; MALE; RECURRENT CANCER; RETROSPECTIVE STUDY; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; HEAD AND NECK TUMOR; METABOLISM; METHODOLOGY; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; RECURRENT DISEASE; SCINTISCANNING; TRANSPORT AT THE CELLULAR LEVEL;

BIOLOGICAL TRANSPORT; CARBON RADIOISOTOPES; CHOLINE; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RECURRENCE; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77958016077     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32833f3921     Document Type: Article

References (28)

1. Marks JE, Phillips JL, Menck HR. The National Cancer Data Base report on the relationship of race and national origin to the histology of nasopharyngeal carcinoma. Cancer 1998; 83:582-588.
2. Ang KK, Trotti A, Brown BW, Garden AS, Foote RL, Morrison WH, et al. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001; 51:571-578.
3. Leemans CR, Tiwari R, Nauta JJP, Van der Waal DDS, Snow GB. Recurrence at the primary site in head and neck cancer and the significant of neck lymph node metastases as a prognostic factor. Cancer 1994; 73:187-190.
4. Ong SC, Schöder H, Lee NY, Patel SG, Carlson D, Fury M, et al. Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for locoregional advanced head and neck cancer. J Nucl Med 2008; 49:532-540.
5. Wong RJ, Lin DT, Schoder H, Patel SG, Gonen M, Wolden S, et al. Diagnostic and prognostic value of [18F] fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol 2002; 20:4199-4208.
6. Abgral R, Querellou S, Potard G, Le Roux PY, Le Duc-Pennec A, Marianovski R, et al. Does 18F-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up? J Nucl Med 2009; 50:24-29.
7. Fakhry N, Lussato D, Jacob T, Giorgi R, Giovanni A, Zanaret M. Comparison between PET and PET/CT in recurrent head and neck cancer and clinical implications. Eur Arch Otorhinolaryngol 2007; 264:531-538.
8. Kubota K, Yokoyama J, Yamaguchi K, Ono S, Qureshy A, Itoh M, et al. FDGPET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT. Eur J Nucl Med Mol Imaging 2004; 31:590-595.
9. Roh JL, Moon BJ, Kim JS, Lee JH, Cho KJ, Choi SH, et al. Use of 18Ffluorodeoxyglucose positron emission tomography in patients with rare head and neck cancers. Clin Exp Otorhinolaryngol 2009; 2:115-119.
10. Khan N, Oriuchi N, Ninomiya H, Higuchi T, Kamada H, Endo K. Positron emission tomographic imaging with 11C-choline in differential diagnosis of head and neck tumors: comparison with 18F-FDG PET. Ann Nucl Med 2004; 18:409-417.
11. Ninomiya H, Oriuchi N, Kahn N, Higuchi T, Endo K, Takahashi K, et al. Diagnosis of tumor in the nasal cavity and paranasal sinuses with [11C]choline PET: comparative study with 2-[18F]fluoro-2-deoxy-D-glucose (FDG) PET. Ann Nucl Med 2004; 18:29-34.
12. Tian M, Zhang H, Oriuchi N, Higuchi T, Endo K. Comparison of 11C-choline PET and FDG PET for the differential diagnosis of malignant tumors. Eur J Nucl Med Mol Imaging 2004; 31:1064-1072.
13. Shinoura N, Nishijima M, Hara T, Haisa T, Yamamoto H, Fujii K, et al. Brain tumors: detection with C-11 choline PET. Radiology 1997; 202:497-503.
14. Hara T, Kosaka N, Suzuki T, Kudo K, Niino H. Uptake rates of 18F-fluorodeoxyglucose and 11C-choline in lung cancer and pulmonary tuberculosis: a positron emission tomography study. Chest 2003; 124:893-901.
15. Lee M, Baum U, Greess H, Nömayr A, Nkenke E, Koester M, et al. Head and neck tumors: imaging recurrent tumor and post-therapeutic changes with CT and MRI. Eur J Radiol 2000; 33:239-247.
16. Lapela M, Eigtved A, JyrkkiöS, Grénman R, Kurki T, Lindholm P, et al. Experience in qualitative and quantitative FDG PET in follow-up of patients with suspected recurrence from head and neck cancer. Eur J Cancer 2000; 36:858-867.
17. Ito K, Yokoyama J, Kubota K, Morooka M, Shiibashi M, Matsuda H. (18)F-FDG versus (11)C-choline PET/CT for the imaging of advanced head and neck cancer after combined intra-arterial chemotherapy and radiotherapy: the time period during which PET/CT can reliably detect non-recurrence. Eur J Nucl Med Mol Imaging 2010; 37:1318-1327.
18. Kubota K. From tumor biology to clinical PET: a review of positron emission tomography (PET) in oncology. Ann Nucl Med 2001; 15:471-486.
19. Roivainen A, Forsback S, Grönroos T, Lehikoinen P, Kähkönen M, Sutinen E, Minn H. Blood metabolism of [methyl-11C]choline; implications for in vivo imaging with positron emission tomography. Eur J Nucl Med 2000; 27:25-32.
20. Aiken NR, Gillies RJ. Phosphomonoester metabolism as a function of cell proliferative status and exogenous precursors. Anticancer Res 1996; 16:1393-1398.
21. Warden CH, Friedkin M. Regulation of choline kinase activity and phosphatidylcholine biosynthesis by mitogenic growth factors in 3T3 fibroblasts. J Biol Chem 1985; 260:6006-6011.
22. Macara IG. Elevated phosphocholine concentration in ras-transformed NIH 3T3 cells arises from increased choline kinase activity, not from phosphatidylcholine breakdown. Mol Cell Biol 1989; 9:325-328.
23. Jeong HS, Chung MK, Son YI, Choi JY, Kim HJ, Ko YH, Baek CH. Role of 18F-FDG PET/CT in management of high-grade salivary gland malignancies. J Nucl Med 2007; 48:1237-1244.
24. Cermik TF, Mavi A, Acikgoz G, Houseni M, Dadparvar S, Alavi A. FDG PET in detecting primary and recurrent malignant salivary gland tumors. Clin Nucl Med 2007; 32:286-291.
25. Hall NC, Kloos RT. PET imaging in differentiated thyroid cancer: where does it fit and how do we use it? Arq Bras Endocrinol Metabol 2007; 51:793-805.
26. Bui CD, Ching AS, Carlos RC, Shreve PD, Mukherji SK. Diagnostic accuracy of 2-[fluorine-18]fluro-2-deoxy-D-glucose positron emission tomography imaging in nonsquamous tumors of the head and neck. Invest Radiol 2003; 38:593-601.
27. Tateishi U, Yamaguchi U, Maeda T, Seki K, Terauchi T, Kawai A, et al. Staging performance of carbon-11 choline positron emission tomography/computed tomography in patients with bone and soft tissue sarcoma: comparison with conventional imaging. Cancer Sci 2006; 97:1125-1128.
28. Otsuka H, Graham MM, Kogame M, Nishitani H. The impact of FDG-PET in the management of patients with salivary gland malignancy. Ann Nucl Med 2005; 19:691-694.